Press Releases

Distributed: Mar 17, 2011

Alerts Login

Melbourne, Mar 17, 2011 (ABN Newswire) - Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that Chief Executive Officer Professor Silviu Itescu has been named BioSpectrum Asia Pacific Person of the Year 2011. BioSpectrum Asia is the leading Asian life sciences publication.

Bio Spectrum's Chief Editor, Dr Narayanan Suresh, said: "The jury's choice of Professor Silviu Itescu, the key mover behind Australia's Mesoblast, one of the global pioneers in developing treatments using adult stem cells, was unanimous."

The Person of the Year Award was judged on meeting award criteria including performance of the organization, role beyond the company, key projects in 2010, global initiatives, influence on policy making, fostering industry harmony and stature as a leader and visionary. The judging panel comprised six global life sciences industry leaders.

Professor Itescu said he was humbled but proud to receive the prestigious award.

"BioSpectrum has recognized Mesoblast's leadership in the global regenerative medicine industry, the tremendous promise of our proprietary adult stem cells to treat major diseases, and the company's ability to grow through valuable strategic alliances," he said.

"The award is most importantly an affirmation of the tremendous effort and dedication from a highly professional and committed team that is responsible for building Mesoblast into a world leading biopharmaceutical company."


About Mesoblast Limited

Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.

Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.

The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.

Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.

Contact

Julie Meldrum
Corporate Communications Director
T: +61-3-9639-6036
C: +61-419-228-128
Email:julie.meldrum@mesoblast.com


  Related Companies

>>>        Mesoblast Limited

  Related Industry Topics:

Biotech | Financial General | Health & Pharm General | 

  This Page Viewed:  (Last 7 Days: 120) (Last 30 Days: 930) (Since Published: 21010) 

Events & Exhibitions

Site Search

 
 ENGLISH   All Languages

Upcoming WebCasts

Mr Mark Paton CEO
Cue Energy Resources
Tuesday, June 12, 2012

Mr Alan Hopkins CEO
Pan Asia Corporation
Tuesday, June 12, 2012

Mr Barry Dawes
Martin Place Securities
Tuesday, June 12, 2012

Dr Andrea Grant CEO
Living Cell Technologies
Monday, July 02, 2012


Webcast Your Annual General Meeting

Mobile Video TV

qrcode
Scan with your Mobile Phone to view ABN Newswire Video Channel on Mobile
 
City Index - A Better Way To Trade